drugset
drugset / Trial / NCT07152873

A Study to Compare to PK Characteristics and Safety Profiles Between AD-117 and AD-117A

NCT07152873 ↗

Phase 1 Not yet recruiting 60 enrolled Addpharma Inc.
RandomizedCrossoverOpen-labelTreatment

Summary

Primary endpoint of this study is to evaluate the pharmacokinetic characteristics of AD-117 in healthy subjects.

Timeline

Start
2025-12-01
Primary completion
2026-02
Completion
2026-03

Drugs

EvaluationDrugModalityDoseRoute
Subject AD-117 Unknown — Oral
Subject AD-117A Unknown — Oral

Indications

hyperlipidemia, combined, 2